SCP
XLRN

Syntal Capital Partners’s Acceleron Pharma XLRN Stock Holding History

Syntal Capital Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,976
Closed -$1.17M – 114
2020
Q1 		$1.17M Buy
+12,976
New +$1.01M 0.77% 35

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Syntal Capital Partners's XLRN Position: Q2 2020 in Review

Syntal Capital Partners sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 12,976 shares — an estimated $1.17M sold.

Syntal Capital Partners first reported a position in XLRN in Q1 2020 and held it in 1 quarter. The position peaked at $1.17M in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

  • Syntal Capital Partners reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
  • Syntal Capital Partners sold 12,976 Acceleron Pharma shares in Q2 2020, an estimated $1.17M.
  • Syntal Capital Partners first reported a position in Acceleron Pharma in Q1 2020 and held it in 1 quarter.
  • Syntal Capital Partners's Acceleron Pharma position peaked at $1.17M in Q1 2020.
  • 242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on Syntal Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.